AAAAAA

   
Results: 1-21 |
Results: 21
Skin test reactivity and cellular immune responses to Mycobacterium avium sensitin in AIDS patients at risk for disseminated M-avium infection
Authors: von Reyn, CF Williams, PL Lederman, HM McCutchan, JA Koletar, SL Murphy, RL Cohn, SE Evans, T Heald, AE Colquhoun, D Bassily, EL Currier, JS
Citation: Cf. Von Reyn et al., Skin test reactivity and cellular immune responses to Mycobacterium avium sensitin in AIDS patients at risk for disseminated M-avium infection, CL DIAG LAB, 8(6), 2001, pp. 1277-1278
A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 X 10(6)/I
Authors: Koletar, SL Heald, AE Finkelstein, D Hafner, R Currier, JS McCutchan, JA Vallee, M Torriani, FJ Powderly, WG Fass, RJ Murphy, RL
Citation: Sl. Koletar et al., A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 X 10(6)/I, AIDS, 15(12), 2001, pp. 1509-1515
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results
Authors: Murphy, RL Brun, S Hicks, C Eron, JT Gulick, R King, M White, AC Benson, C Thompson, M Kessler, HA Hammer, S Bertz, R Hsu, A Japour, A Sun, E
Citation: Rl. Murphy et al., ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results, AIDS, 15(1), 2001, pp. F1-F9
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir- experienced subjects: AIDS Clinical Trials Group protocol 373
Authors: Gulick, RM Smeaton, LM D'Aquila, RT Eron, JJ Currier, JS Gerber, JG Acosta, E Sommadossi, JP Tung, R Snyder, S Kuritzkes, DR Murphy, RL
Citation: Rm. Gulick et al., Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir- experienced subjects: AIDS Clinical Trials Group protocol 373, J INFEC DIS, 183(5), 2001, pp. 715-721
Critical issues surrounding treatment in the era of active antiretroviral therapeutics - Proceedings of a Northwestern University Medical School conference - Introduction
Authors: Murphy, RL
Citation: Rl. Murphy, Critical issues surrounding treatment in the era of active antiretroviral therapeutics - Proceedings of a Northwestern University Medical School conference - Introduction, CLIN INF D, 30, 2000, pp. S95-S95
The impact of co-infection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy
Authors: Melvin, DC Lee, JK Belsey, E Arnold, J Murphy, RL
Citation: Dc. Melvin et al., The impact of co-infection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy, AIDS, 14(4), 2000, pp. 463-465
New antiretroviral drugs in development
Authors: Murphy, RL
Citation: Rl. Murphy, New antiretroviral drugs in development, AIDS, 14, 2000, pp. S227-S234
Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370
Authors: Kuritzkes, DR Bassett, RL Johnson, VA Marschner, IC Eron, JJ Sommadossi, JP Acosta, EP Murphy, RL Fife, K Wood, K Bell, D Martinez, A Pettinelli, CB
Citation: Dr. Kuritzkes et al., Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370, AIDS, 14(11), 2000, pp. 1553-1561
A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of thymidine analog regimen therapy (START II)
Authors: Eron, JJ Murphy, RL Peterson, D Pottage, J Parenti, DM Jemsek, J Swindells, S Sepulveda, G Bellos, N Rashbaum, BC Esinhart, J Schoellkopf, N Grosso, R Stevens, M
Citation: Jj. Eron et al., A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of thymidine analog regimen therapy (START II), AIDS, 14(11), 2000, pp. 1601-1610
Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy - A randomized controlled trial
Authors: Davey, RT Murphy, RL Graziano, FM Boswell, SL Pavia, AT Cancio, M Nadler, JP Chaitt, DG Dewar, RL Sahner, DK Duliege, AM Capra, WB Leong, WP Giedlin, MA Lane, HC Kahn, JO
Citation: Rt. Davey et al., Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy - A randomized controlled trial, J AM MED A, 284(2), 2000, pp. 183-189
The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850)
Authors: Eron, JJ Smeaton, LM Fiscus, SA Gulick, RM Currier, JS Lennox, JL D'Aquila, RT Rogers, MD Tung, R Murphy, RL
Citation: Jj. Eron et al., The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850), J INFEC DIS, 181(5), 2000, pp. 1622-1628
Lopinavir - A viewpoint by Robert L. Murphy - Guest commentary
Authors: Murphy, RL
Citation: Rl. Murphy, Lopinavir - A viewpoint by Robert L. Murphy - Guest commentary, DRUGS, 60(6), 2000, pp. 1380-1381
Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count - A randomized, double-blind, placebo-controlled trial
Authors: Currier, JS Williams, PL Koletar, SL Cohn, SE Murphy, RL Heald, AE Hafner, R Bassily, EL Lederman, HM Knirsch, C Benson, CA Valdez, H Aberg, JA McCutchan, JA
Citation: Js. Currier et al., Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count - A randomized, double-blind, placebo-controlled trial, ANN INT MED, 133(7), 2000, pp. 493-503
Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm(3)
Authors: Pollard, RB Peterson, D Hardy, D Pottage, J Murphy, RL Gathe, J Beall, G Rutkievicz, V Reynolds, L Cross, AP Dunkle, LM
Citation: Rb. Pollard et al., Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm(3), J ACQ IMM D, 22(1), 1999, pp. 39-48
Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks
Authors: Murphy, RL
Citation: Rl. Murphy, Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks, ANTIVIR TH, 4, 1999, pp. 85-87
Lamivudine in combination with zidovudine stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial
Authors: Kuritzkes, DR Marschner, I Johnson, VA Bassett, R Eron, JJ Fischl, MA Murphy, RL Fife, K Maenza, J Rosandich, ME Bell, D Wood, K Sommadossi, JP Pettinelli, C
Citation: Dr. Kuritzkes et al., Lamivudine in combination with zidovudine stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial, AIDS, 13(6), 1999, pp. 685-694
Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1
Authors: Murphy, RL Sommadossi, JP Lamson, M Hall, DB Myers, M Dusek, A
Citation: Rl. Murphy et al., Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1, J INFEC DIS, 179(5), 1999, pp. 1116-1123
Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection
Authors: Murphy, RL Gulick, RM DeGruttola, V D'Aquila, RT Eron, JJ Sommadossi, JP Currier, JS Smeaton, L Frank, I Caliendo, AM Gerber, JG Tung, R Kuritzkes, DR
Citation: Rl. Murphy et al., Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection, J INFEC DIS, 179(4), 1999, pp. 808-816
A family history study of male sexual orientation using three independent samples
Authors: Bailey, JM Pillard, RC Dawood, K Miller, MB Farrer, LA Trivedi, S Murphy, RL
Citation: Jm. Bailey et al., A family history study of male sexual orientation using three independent samples, BEHAV GENET, 29(2), 1999, pp. 79-86
Stavudine-based multiple agent combinations: initial studies and ongoing comparative trials
Authors: Murphy, RL
Citation: Rl. Murphy, Stavudine-based multiple agent combinations: initial studies and ongoing comparative trials, ANTIVIR TH, 3, 1998, pp. 69-73
Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both
Authors: El-Sadr, WM Murphy, RL Yurik, RM Luskin-Hawk, R Cheung, TW Balfour, HH Eng, R Hooton, TM Kerkering, TM Schutz, M van der Horst, C Hafner, R
Citation: Wm. El-sadr et al., Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both, N ENG J MED, 339(26), 1998, pp. 1889-1895
Risultati: 1-21 |